Trial Profile
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Momelotinib (Primary) ; Ruxolitinib
- Indications Anaemia; Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms Simplify 2
- Sponsors Gilead Sciences; Sierra Oncology
- 12 Dec 2023 Results of pooled analysis from SIMPLIFY-1 and SIMPLIFY-2 , applying time without transfusion reliance (TWiTR) analyses, integrating transfusion-dependent (TD) status and OS, to further characterize the benefits of MMB on survival quality.presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results demonstrating the prognostic influence of RBC transfusion status and other covariates on overall survival SIMPLIFY-1 (S1), SIMPLIFY-2 (S2), and MOMENTUM studies presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of post hoc subgroup analysis (n=105) assessing Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions presented at the 65th American Society of Hematology Annual Meeting and Exposition